Topo
Este site usa cookies
Os cookies que usamos permitem usufruir de todas funcionalidades e ter uma boa experiência de utilização. Os cookies essenciais são imprescindíveis para o bom funcionamento do site e só podem ser desativados alterando as preferências do browser. Os cookies analíticos recolhem e analisam informação sobre a utilização do site, de forma anónima, que nos ajuda a melhorar a experiência de navegação.
Aceita cookies analíticos?
Serviço Nacional de Saúde
República Portuguesa

Hospital Beatriz Ângelo

Navegação Principal do site

Ensaios clínicos em recrutamento


Ensaios clínicos na área do carcinoma mama
  • XENERA-1: A multi-centre, double-blind, placebo-controlled, randomised phase II trial to compare efficacy of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in post-menopausal women with HR+ / HER2- metastatic breast cancer and non-visceral disease. Mais informações em https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-003131-11/PT

  • Violette: A Phase II, Open Label, Randomised, Multi-centre Study to Assess the Safety and Efficacy of Agents Targeting DNA Damage Repair in Combination with Olaparib versus Olaparib Monotherapy in the Treatment of Metastatic Triple Negative Breast Cancer Patients Stratified by Alterations in Homologous Recombinant Repair (HRR)-related Genes (including BRCA1/2). Mais informações em https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-002361-22/PT
Ensaios clínicos na área da colite ulcerosa

  • GS-US-418-4279: Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Testicular Safety of Filgotinib in Adult Males with Moderately to Severely Active Ulcerative Colitis. Mais informações em https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-000402-38/PT

Ensaios clínicos na área da doença de Crohn
  • GS-US-419-3895: Combined Phase 3, Double-blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects with Moderately to Severely Active Crohn’s Disease. Mais informações em: https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-001367-36/PT
  • M15-991: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study to Assess the Efficacy and Safety of Risankizumab in Subjects with Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment. Mais informações em https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003190-17/PT
  • M16-006: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study of the Efficacy and Safety of Risankizumab in Subjects with Moderately to Severely Active Crohn's Disease. Mais informações em https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003123-32/PT

Ensaios clínicos na área da endometriose
Ensaios clínicos na área das infeções respiratórias
  • PROMIS I: A double-blind, placebo controlled, multicentre, clinical trial to investigate the efficacy and safety of 12 months of therapy with inhaled Promixin® (colistimethate sodium) in the treatment of subjects with non-cystic fibrosis bronchiectasis chronically infected with Pseudomonas aeruginosa (P. aeruginosa). Mais informações em: https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-002743-33/PT


Ensaios clínicos na área da doença renal             
  • AKB-6548-CI-0016: Phase 3, Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy and Safety of Oral Vadadustat for the Correction of Anemia in Subjects with Incident Dialysis Dependent Chronic Kidney Disease (DD-CKD). Mais informações em: https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-000838-21/PT 

  • TRCA-303: A Phase 3b, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of TRC101 in Delaying Chronic Kidney Disease Progression in Subjects with Metabolic Acidosis. Mais informações em https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-001303-36/PT

  • STAGED: Multicenter, randomized, double-blind, placebo-controlled two stage study to characterize the efficacy, safety, tolerability and pharmacokinetics of GZ/SAR402671 in patients at risk of rapidly progressive Autosomal Dominant Polycystic Kidney Disease (ADPKD). Mais informações em https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-004084-12/PT

  • BI1378-0008: Randomised, double-blind, placebo-controlled (within dose groups) and active controlled (eplerenone group) trial to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of 4 oral doses of BI 690517 over 28 days in female and male patients with diabetic nephropathy. Mais informações em https://clinicaltrials.gov/ct2/show/NCT03165240?term=BI+1378-0008&rank=1

voltar